Birnbaum, Y., Bajaj, M., Yang, H.-C. and Ye, Y. (2018) Combined SGLT2 and DPP4 Inhibition Reduces the Activation of the Nlrp3/ASC Inflammasome and Attenuates the Development of Diabetic Nephropathy in Mice with Type 2 Diabetes. Cardiovascular Drugs and Therapy, 32, 135-145.
http://link.springer.com/10.1007/s10557-018-6778-x
https://doi.org/10.1007/s10557-018-6778-x

has been cited by the following article:

• TITLE: Dipeptidyl Peptidase-4 Inhibitors and Inflammation: Dpp-4 Inhibitors Improve Mean Pleatelet Volume and Gamma Glutamyl Transferase Level

  AUTHORS: Deniz Avcı

  KEYWORDS: DPP-4 Inhibitors, MPV, GGT, Inflammation, Diabetes Mellitus

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.7 No.2, January 24, 2019

  ABSTRACT: AIM: The purpose of this research was to determine the changes of the inflammatory parameters in the long term with the use of dipeptidyl peptidase-4 inhibitors. Material and Methods: In this research we have retrospectively reviewed the records of 80 patients who had added dipeptidyl peptidase-4 inhibitors (40 sitagliptin and 40 vildagliptin) to their ongoing therapies. Patients’ values of inflammation at the beginning of this process were taken as initial values, while values at the end of this process were considered as final values. Results: A total of 80 patients [38.8% (n = 31) of the patients were male, while 61.3% (n = 49) were female] enrolled in the study. When the whole group was evaluated, the mean age was 56.1 ± 9.7 years. The median follow-up time of the patients with DPP-4 inhibitors was 18 (2 - 64) months. The mean MPV value was measured as 8.79 ± 1.71 fL before DPP-4 inhibitors and it was 10.06 ± 1.42 fL after the follow-up period (p